#Sweden #AGM #Stockholm #Leqembi #BioArctic

BioArctic AB's Annual General Meeting: Key Highlights

On May 28, 2026, BioArctic AB (publ), listed on Nasdaq Stockholm as BIOA B, convened its Annual General Meeting (AGM) in the vibrant city of Stockholm. This gathering was pivotal for stakeholders and investors as the board presented crucial resolutions that shape the company's future.
The AGM commenced with the adoption of the income statement and balance sheet for both the company and the group, following the approval of related accounting documents. In line with the board’s proposals, the meeting also resolved to issue a dividend of SEK 2 per share, with June 1, 2026, set as the record date for this distribution.

One significant agenda point was the discharge of liability for the board of directors and the CEO concerning operations throughout the fiscal year of 2025. The assembly overwhelmingly supported this motion, reaffirming the board's governance during the period.

Board of Directors Resolutions

The AGM saw the re-election of ordinary board members including Eugen Steiner, Cecilia Edström, Anna-Lena Engwall, Lars Lannfelt, Lotta Ljungqvist, and Mikael Smedeby, along with the nomination of new members Philip Scheltens and Linda Nilsson. These appointments are effective until the conclusion of the next AGM, with Eugen Steiner retaining his role as chairperson of the board.

The remuneration for the board was also established, allocating SEK 875,000 for the chairperson and SEK 315,000 for each of the other board members not employed by the company. The meeting also determined respective payments for committee chairs and members, demonstrating a structured approach to compensation aligned with company performance.

Auditor Appointment and Remuneration

Furthermore, the AGM appointed Öhrlings PricewaterhouseCoopers AB (PwC) as the company's auditor until the next AGM, with Niclas Bergenmo designated as the auditor in charge. The auditor’s remuneration will be settled upon receipt of approved invoices, ensuring financial oversight accountability.

New Incentive Program

A noteworthy development was the introduction of a three-year incentive program aimed at engaging employees. This program is contingent upon operational performance and employee retention, presenting a unique opportunity for up to 235,000 performance-based share units (PSUs) to be allocated based on the fulfillment of specific comprehensive performance criteria. The criteria include share price appreciation and operational benchmarks related to research developments.

Share Issuance Authorization

In a move designed to facilitate financial agility and future growth, the AGM authorized the board to resolve on issues of new shares, warrants, or convertibles up to a limit of ten percent of the current share capital. This authorization provides BioArctic with the flexibility needed to respond to market demands while considering shareholder interests.

Remuneration Guidelines Update

Lastly, the AGM approved updated guidelines for executive remuneration, reinforcing the board's authority to award additional variable compensation under exceptional circumstances. This move indicates BioArctic's commitment to recognizing extraordinary efforts and results, with the total variable remuneration capped at 150 percent of the CEO's salary and 80 percent for other senior executives.

In conclusion, the AGM of BioArctic AB not only reflected the company's robust growth strategy but also underscored its commitment to shareholders and employees alike through responsible governance and strategic planning. Moving forward, stakeholders will be keenly observing how these resolutions translate into actual performance and growth for the company, particularly in its cutting-edge research in neurodegenerative diseases, notably with Leqembi, the world's first drug to slow the progression of early Alzheimer's disease.

For further details, stakeholders can contact Oskar Bosson, VP of Communications, or Anders Martin-Löf, CFO, whose contact information was made public during the meeting. BioArctic's journey continues to unfold, promising exciting advancements in the biopharma sector.